TLDR Oral tofacitinib significantly improves lichen planopilaris symptoms without adverse effects.
The study investigated the efficacy of oral tofacitinib in treating lichen planopilaris (LPP), a type of lymphocytic scarring alopecia. Eight patients were treated, showing significant improvement in the LPP activity index (LPPAI) by 30-94% (p=0.0014). Some patients required increased dosage for a measurable response. LPP symptoms flared upon withdrawal of tofacitinib but were controlled again upon re-initiation. No adverse effects or significant changes in laboratory values were reported. The findings suggested that JAK inhibitors like tofacitinib could be a promising treatment for LPP, warranting further randomized placebo-controlled trials.
79 citations,
September 2018 in “Dermatologic therapy” Oral tofacitinib can significantly improve recalcitrant lichen planopilaris.
13 citations,
April 2022 in “Anais brasileiros de dermatologia/Anais Brasileiros de Dermatologia” The document concludes that more research is needed to find effective treatments for Lichen planopilaris and Frontal fibrosing alopecia.
May 2023 in “Journal of Clinical Medicine” New understanding and treatments for hair loss are improving, but more research is needed.
April 2018 in “The journal of investigative dermatology/Journal of investigative dermatology” Samcyprone ointment is effective for treating common warts if a sensitization reaction occurs first.
August 2023 in “Journal of The American Academy of Dermatology” Early treatment is key for permanent hair loss disorders, with options ranging from medications and phototherapy to immunomodulators and antibiotics, depending on severity and type.
